Inventiva et Hepalys Pharma, Inc., signent un accord de licence exclusif pour développer et commercialiser lanifibranor au Japon et en Corée du Sud
20 sept. 2023 16h00 HE
|
INVENTIVA
Hepalys Pharma, Inc. est une nouvelle société créée par Catalys Pacific, et dans laquelle Inventiva détient une participation de 30%. Dans le cadre de l’accord de licence exclusif, Inventiva...
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
20 sept. 2023 16h00 HE
|
INVENTIVA
Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position. Under the exclusive licensing agreement, Inventiva will receive a $10 million...
The Human Rights and Rights to Religious Freedom of 600,000 Japanese Citizens are at Risk
19 sept. 2023 22h04 HE
|
Center for Studies on New Religions, "Bitter Winter"
Washington, DC, Sept. 19, 2023 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE Center for Studies on New Religions, Human Rights and Religious Freedom Experts Decry Government Persecution of...
The Human Rights and Rights to Religious Freedom of 600,000 Japanese Citizens are at Risk
19 sept. 2023 14h07 HE
|
Center for Studies on New Religions, "Bitter Winter"
Washington, DC, Sept. 19, 2023 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE Center for Studies on New Religions, Human Rights and Religious Freedom Experts Decry Government Persecution of...
ClimateAi Announces Expanded Presence in Japan to Advance Climate Resilience Solutions
14 sept. 2023 07h00 HE
|
ClimateAi
SAN FRANCISCO, Sept. 14, 2023 (GLOBE NEWSWIRE) -- ClimateAi, one of the fastest-growing climate resilience software service providers, today announced the expansion of its presence in Japan with a...
サリプロ・バイオテック (Salipro Biotech)、住友ファーマと研究提携を締結し、創薬プログラムを推進
12 sept. 2023 02h00 HE
|
Salipro Biotech AB
本提携では、サリプロ・バイオテックの独自の専門知識とSalipro®プラットフォーム技術を活用して困難な薬物標的を安定化し、住友ファーマの創薬プログラムによる化合物の薬理学的特性を研究 する。 スウェーデン・ストックホルム発, Sept. 12, 2023 (GLOBE NEWSWIRE) -- スウェーデンのバイオテクノロジー企業であるサリプロ・バイオテックAB (Salipro...
Salipro Biotech geht Forschungskooperation mit Sumitomo Pharma zum Vorantreiben eines Medikamentenentwicklungsprogramms ein
12 sept. 2023 02h00 HE
|
Salipro Biotech AB
Die Zusammenarbeit nutzt die einzigartige Expertise von Salipro Biotech und die Salipro®-Plattformtechnologie zur Stabilisierung eines anspruchsvollen Wirkstoffziels, um die pharmakologischen...
Salipro Biotech collabore avec Sumitomo Pharma pour développer un programme de recherche de médicaments
12 sept. 2023 02h00 HE
|
Salipro Biotech AB
La collaboration mobilise l'expertise unique de Salipro Biotech et sa plateforme technologique Salipro® pour stabiliser une cible pharmacologique difficile. Objectif : étudier les caractéristiques...
Salipro Biotech enters into research collaboration with Sumitomo Pharma to advance a drug discovery program
12 sept. 2023 02h00 HE
|
Salipro Biotech AB
The collaboration leverages Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilize a challenging drug target to investigate the pharmacological characteristics of a...
Matterport’s Digital Twin Platform Documents Reconstruction of 2,000 Year-Old Aso Shrine Following Earthquake Collapse
05 sept. 2023 09h00 HE
|
Matterport Inc
SUNNYVALE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Matterport, Inc. (Nasdaq: MTTR), today announced it has captured the restored Aso Shrine Gate and surrounding shrine area as part of an...